Cancer is the second-leading cause of death in the United States (U.S.) after heart disease. It is estimated that nearly 1.7 million people in the country will be diagnosed with cancer in 2014, and that approximately 585,720 will die from the disease. In the fight against cancer, diagnostic ultrasound imaging, minimally invasive biopsy, and tissue screening are among the methods that allow physicians to detect malignancies at their earliest and most treatable stages.
In 2012, approximately 92.0 million oncology-related diagnostic ultrasound, minimally invasive biopsy, and tissue screening procedures were performed in the U.S. Together, these procedures generated approximately $1.1 billion in corresponding product sales; it is expected that during the forecast period covered by this report, sales of diagnostic ultrasound, minimally invasive biopsy, and tissue screening products for oncology-related indications will increase at a compound annual rate of 3.9%, reaching nearly $1.4 billion in the year 2017.
This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic ultrasound, minimally invasive biopsy, and tissue screening products arena.
Covered topics in this report include an overview of cancer in the U.S. including discussions of the different forms of the disease; automated and semi-automated tissue screening technologies; capacitive micromachined ultrasonic transducers; contrast-enhanced ultrasound; core needle biopsy systems; diagnostic ultrasound systems; Doppler and tissue harmonic imaging; fine-needle aspiration; human papilloma virus testing systems; minimally invasive biopsy; Papanicolaou smear testing systems; photoacoustic imaging; risk factors for cancer development; statistics covering new cancer cases, cancer prevalence, and cancer-related deaths; tissue elastography; and vacuum-assisted biopsy systems; among others
Browse more Ultra Sound Market Research Reports